** Shares of Kintara Therapeutics more than double to $0.21 premarket
** Co to merge with privately held TuHURA Biosciences, with merger expected to close in Q3
** KTRA equityholders expected to collectively own up to ~2.85%, or ~5.45% if certain milestones are met, while TuHURA equityholders are expected to collectively own ~97.15%, or 94.55% if the milestones are met
** TuHURA expects its experimental cancer vaccine to enter a late-stage trial as adjunct therapy with Merck's cancer drug Keytruda, with enrollment in the study to start in H2
The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on Nasdaq under the ticker "HURA"
** Up to last close, KTRA stock down 40.8% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Comments